MedTrace Logo

Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers

NCT04485481 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-07-28

No results posted yet for this study

Summary

A two (2) part study to evaluate the safety, tolerability and PK of ADX-914

Conditions

  • Safety Issues

Interventions

DRUG

ADX-914

Single dose from 0.1mg/kg to TBD

DRUG

Placebo

Matching single dose placebo

DRUG

ADX-914

Multiple dose from TBD to TBD

DRUG

Placebo

Matching multiple dose placebo

Sponsors & Collaborators

  • Q32 Bio Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-08
Primary Completion
2022-01-12
Completion
2022-01-12

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04485481 on ClinicalTrials.gov